— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver ...

As AI becomes more prevalent, organizations need to leverage the power of scope, scale, speed, and human-AI collaboration for differentiation. In partnership withZS and AWS Inspired by an ...

From automating content creation and personalization at scale to accelerating drug discovery and material design ... innovations. At AWS, we believe that generative AI should be accessible ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the ...

He discusses how Exscientia’s approach has evolved from a singular focus to an end-to-end process for improving drug design and development with AI. Hopkins and host Jonah Comstock also get into ...

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

It also offers a set of design principles for generative AI workflows created on AWS, specifically highlighting the need for controlled autonomy, which is particularly relevant to AI workloads.

in charge of building AWS generative AI products and increasing sales pipeline. “I had the privilege of advising our biggest customers on their AI execution and serving as a key design partner ...

AWS CEO Matt Garman announced the appointment internally on Wednesday, in an email leaked to Reuters. He promoted the formation of the new division as critical for Amazon’s push into cloud AI ...